Minimal residual disease surveillance at day 90 predicts long-term survival in pediatric patients with T-cell acute lymphoblastic leukemia

2020 ◽  
Vol 61 (14) ◽  
pp. 3460-3467
Author(s):  
Xiaoming Liu ◽  
Yao Zou ◽  
Xiaojuan Chen ◽  
Shuchun Wang ◽  
Ye Guo ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
T Cell ◽  
Disease Surveillance ◽  
Pediatric Patients ◽  
Residual Disease ◽  
Lymphoblastic Leukemia ◽  
Term Survival ◽  
Cell Acute Lymphoblastic Leukemia ◽  
Minimal Residual

scholarly journals DNA Methylation Adds Prognostic Value to Minimal Residual Disease Status in Pediatric T‐Cell Acute Lymphoblastic Leukemia

2016 ◽  
Vol 63 (7) ◽  
pp. 1185-1192 ◽  
Author(s):  
Magnus Borssén ◽  
Zahra Haider ◽  
Mattias Landfors ◽  
Ulrika Norén‐Nyström ◽  
Kjeld Schmiegelow ◽  
...  
Keyword(s):  
Dna Methylation ◽  
Acute Lymphoblastic Leukemia ◽  
T Cell ◽  
Minimal Residual Disease ◽  
Prognostic Value ◽  
Residual Disease ◽  
Lymphoblastic Leukemia ◽  
Disease Status ◽  
Cell Acute Lymphoblastic Leukemia ◽  
Minimal Residual

scholarly journals Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment

Blood ◽  
2015 ◽  
Vol 126 (24) ◽  
pp. 2578-2584 ◽  
Author(s):  
Gerhard Zugmaier ◽  
Nicola Gökbuget ◽  
Matthias Klinger ◽  
Andreas Viardot ◽  
Matthias Stelljes ◽  
...  
Keyword(s):  
T Cell ◽  
Cell Kinetics ◽  
Residual Disease ◽  
Lymphoblastic Leukemia ◽  
Term Survival ◽  
Long Term Survival ◽  
Disease Response ◽  
Key Points ◽  
Minimal Residual

Key Points Ten of 36 patients (28%) achieved an OS ≥30 months in a blinatumomab study in relapsed/refractory acute lymphoblastic leukemia. Long-term survival may be associated with T-cell expansion, B-cell depletion, and a minimal residual disease response.

Sign in / Sign up

Export Citation Format

Share Document